BETHLEHEM, Pa., May 03, 2017 -- B. Braun Medical Inc. will sponsor three educational programs at the Infusion Nurses Society (INS) Spring 2017 Conference that focus on a critical step to peripheral vascular access success, as well as hazardous drug safety. The INS conference is being held May 6-8 at the Minneapolis Convention Center in Minnesota.
In collaboration with Christie Medical Holdings, Inc., B. Braun will present two events directed at improving peripheral vascular access through optimal site assessment.
- An Exhibitor Product Theater CE presentation entitled “Transforming Peripheral Vascular Access” will be held 12:40 to 1:30 p.m. Saturday, May 6, at the rear of the exhibit hall. The presenter is Gregory J. Schears, M.D., Associate Professor of Anesthesiology in Rochester, Minnesota. One CE credit will be offered for this presentation.
- A Simulation Lab event entitled “Targeting Vein Preservation and Optimal Site Choice with Technology” will be held 10:45 a.m. to noon on Sunday, May 7, on the exhibit hall show floor. This program also will be presented by Dr. Schears.
To learn more, visit www.bbrauninsspring.com.
Christie and B. Braun recently announced an alliance, whereby B. Braun will sell the Christie VeinViewer® to hospitals in the United States. VeinViewer technology complements B. Braun’s infusion therapy product line by addressing the first step in peripheral IV therapy success by helping the clinician select the best vein for placing an IV catheter.
“As a leader in infusion therapy, we are committed to facilitating the sharing of knowledge between healthcare professionals,” said Tom Sutton, Vice President of Vascular Access Systems at B. Braun. “By collaborating with Christie and offering these programs at INS, our goal is to bring healthcare experts and practitioners together to discuss current issues and advance clinical PIV knowledge that helps to improve outcomes, as well as the quality, efficiency and safety of healthcare delivery.”
B. Braun also will sponsor a CNE presentation for the INS Daybreak Symposium from 7 to 7:50 a.m. on Tuesday, May 9, in Ballroom A of the Minneapolis Convention Center. “Ready for USP <800>? The Next Chapter in Hazardous Drug Safety” will be presented by Shawn Becker, MS, BSN, Senior Director of Healthcare Quality and Safety, United States Pharmacopeia (USP).
To advance USP <800> awareness and education, B. Braun also will feature the new Readyfor800.com website at the company’s booth (#613). The educational resource provides information that will help prepare clinicians for the new USP <800> guidelines that enhance hazardous drug safety for clinicians and patients. Visitors also will be able to learn about the role of a closed system transfer device (CSTD) and the advantages of B. Braun’s OnGuard® CSTD.
Also at booth #613, B. Braun will showcase the pathway and products that can lead to successful peripheral IV therapy, including the Christie VeinViewer (Christie booth #713), Introcan Safety® family of PIV catheters, STEADYCare™ extension set with the Wedge™ catheter stabilizer, Ster-ASSIST™ sterile peripheral IV catheter insertion kit, CARESITE® luer access device, and InVision-Plus CS® needleless connector.
*VeinViewer is a registered trademark of Christie Medical Holdings, Inc.
Christie is the manufacturer and B. Braun is a distributor of VeinViewer.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]


Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices
Microsoft Restores Microsoft 365 Services After Widespread Outage
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 



